Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
01/05/15
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/05/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc. , that stock options to purchase an aggregate of 114,500 of the Company's
12/09/14
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/09/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc. , a reminder that the Company will host an Investor and Analyst Day for
12/03/14
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/03/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc. , that stock options to purchase an aggregate of 104,800 of the Company's
11/20/14
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/20/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc. , that the Company will host an Investor and Analyst Day for the
11/12/14
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/12/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc. , that Rick E Winningham, Theravance Biopharma's chief executive officer,
11/06/14

Progress in Priority Portfolio Programs; Investor & Analyst Day Planned for December 12th

11/03/14

240 mg Achieved a Median Maximal Viral Load Decline of 4.9 Log10 IU/mL Following Three Daily Doses in Genotype 1a Patients

10/30/14
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/30/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its US operating subsidiary, Theravance Biopharma US, Inc. , that it will release financial results for the period ended September 30,
09/09/14

Plans for New Clinical Studies, Expanded Commercial Program and New Study Analyses Further Supporting Drug's in Vitro Potency in Resolving Difficult-to-Treat Infections

09/08/14

Primary and Secondary Efficacy Endpoints Met for Doses 88 mcg and Above; TD-4208 Demonstrates Clear Dose-Response Relationship and FEV1 Profile Consistent with Once-Daily Dosing